Journal of diabetes and metabolic disorders

Effects and safety of GLP-1 drugs on heart and metabolism health in overweight or obese Chinese adults

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with substantial weight loss and metabolic benefits in overweight and obese populations.

  • The efficacy of GLP-1RAs in improving cardio-metabolic health in Chinese adults is not fully understood.
  • There may be differences in the response to GLP-1RAs based on population characteristics.
  • Further research is needed to clarify the safety profile of GLP-1RAs in this demographic.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

0 of 10
authors report competing interests
10 report none
PubMed
No competing interests reported.

Related papers

Sep '25
Effect of lifestyle changes and GLP-1 drugs on weight and heart health markers in people with overweight or obesity
top 2% journal
cited by 12 papers
journal article
Mar '23
Effectiveness and safety of GLP-1 drugs compared to SGLT-2 drugs in overweight or obese patients with and without diabetes
top 20% journal
cited by 87 papers
systematic review
Sep '23
Weight loss from GLP-1 receptor drugs in non-diabetic people with overweight or obesity: A combined analysis of clinical trials
cited by 88 papers
systematic review
Feb '25
Comparing how incretin drugs affect blood sugar, weight, and blood pressure in overweight adults with or without type 2 diabetes
top 10% journal
cited by 15 papers
systematic review
Sep '25
Incretin-Based Treatments and Their Impact on Blood Pressure: A Summary and Analysis
top 5% journal
cited by 2 papers
journal article
Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 30 papers
systematic review
Mar '21
Weight Loss Treatments for Overweight or Obese People with Chronic Kidney Disease
cited by 19 papers
systematic review
Oct '25
Tirzepatide treatment for adults with obesity
cited by 3 papers
systematic review
Oct '25
Liraglutide treatment for adults with obesity
cited by 2 papers
systematic review

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief